The last recurrence in the long-term study occurred at 5.4 years, leading researchers to be more comfortable using the term ...
Vertex Pharmaceuticals and CRISPR Therapeutics' gene-editing drug is the only sickle cell disease gene therapy on the market for young children.
During its research day, the firm discussed a cell therapy effort in lupus, dubbed "007," and an AI platform for gleaning ...
NEW YORK – Roche will share with regulators data from a Phase III trial of its KRAS G12C inhibitor divarasib, showing its ability to keep lung cancer patients alive longer without progression compared ...
The firm has raised $78 million to date and is launching its first clinical trial to test a treatment for ...
The agency expects to issue decisions on Vyondys 53 and Amondys 45, which missed their primary endpoint in a confirmatory trial, by February 2027.
The program will help make genetic counselors available to any provider across different medical specialties in Tennessee and ...
Despite fears of an innovation slowdown, stoked by funding cuts and FDA personnel shakeups, the agency approved 17 ...
NEW YORK – Natera's circulating tumor DNA (ctDNA) test Signatera will be used to measure minimal residual disease in Aveta Biomics' Phase III trial of an immunotherapy for locally advanced head and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results